Frontiers in allergy最新文献

{"title":"Contemporary office-based procedures in rhinology: a narrative review of techniques, indications, and outcomes.","authors":"Ghassan Alokby","doi":"10.3389/falgy.2025.1554792","DOIUrl":"10.3389/falgy.2025.1554792","url":null,"abstract":"<p><strong>Background: </strong>The role of office-based procedures in rhinology has expanded considerably, driven by advancements in minimally invasive techniques and a growing emphasis on value-based care. These interventions can offer effective management for selected sinonasal conditions while reducing reliance on operating room resources.</p><p><strong>Objective: </strong>To provide a comprehensive narrative review of contemporary office-based rhinologic procedures, focusing on indications, anesthetic considerations, patient selection, and safety protocols. Additionally, to share institutional experience, highlighting practical benefits in workflow optimization and patient access.</p><p><strong>Methods: </strong>A narrative review was conducted by searching PubMed, Embase, and Scopus databases for English-language articles published between [2010-2025] using the keywords: <i>office-based rhinology</i>, <i>balloon sinuplasty</i>, <i>cryotherapy</i>, <i>radiofrequency neurolysis</i>, <i>nasal valve collapse</i>, and <i>Eustachian tube dilation</i>. Priority was given to clinical studies, systematic reviews, and guidelines relevant to procedural safety, efficacy, and healthcare resource utilization. Additionally, institutional data from King Faisal Specialist Hospital and Research Centre (KFSHRC) were reviewed to illustrate real-world application.</p><p><strong>Results: </strong>The review highlights key office-based procedures, their indications, contraindications, anesthetic strategies, and safety considerations. Institutional experience demonstrated a 140% increase in office-based procedures over two years, reduced waiting times, and improved operating room efficiency, particularly for routine turbinate surgeries.</p><p><strong>Conclusion: </strong>Office-based rhinologic procedures offer safe, effective, and resource-efficient alternatives for selected patients. While current evidence and institutional experiences are promising, further research is warranted to standardize practice, evaluate long-term outcomes, and assess economic impacts across healthcare systems.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1554792"},"PeriodicalIF":3.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Galectin-9: diverse roles in skin disease.","authors":"Lin Wang, Chuqiao Zhang, Jiang Ji, Qingqing Jiao","doi":"10.3389/falgy.2025.1614277","DOIUrl":"10.3389/falgy.2025.1614277","url":null,"abstract":"<p><p>Galectin-9 (Gal-9) is a multifunctional immunomodulatory molecule involved in cell growth, differentiation, adhesion, communication, and death. Galectin-9 mediates its physiological functions through interactions with multiple membrane receptors, including T-cell immunoglobulin mucin-domain containing-3 (Tim-3), immunoglobulin E, and the hyaluronan receptor CD44. In recent years, Gal-9 has been extensively studied in autoimmune diseases, tumor microenvironments, and viral infections. The circulating levels of this lectin demonstrate clinical correlation with disease progression in both acute and chronic infectious conditions. In addition, Gal-9 can potentially be a reliable, sensitive, and noninvasive biomarker of disease severity in many skin diseases. However, there has not been a review of Gal-9 studies in patients with dermatosis. This review summarizes recent advances in understanding Gal-9's immunomodulatory mechanisms in chronic spontaneous urticaria pathophysiology, systemic lupus erythematosus, atopic dermatitis, melanoma, systemic sclerosis, herpes simplex virus infection, bullous pemphigoid, psoriasis, vitiligo, maculopapular exanthema, and skin grafting to provide a reference for future research. Gal-9 is an important regulator of immune homeostasis whose level changes significantly in many skin diseases, and validation was performed in a mouse model using exogenous Gal-9. Ongoing studies are necessary to clarify the pathophysiology of Gal-9, identify the potential of Gal-9 as a new biomarker, and develop new therapeutic approaches for skin diseases.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1614277"},"PeriodicalIF":3.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12307340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota-metabolome crosstalk in allergic diseases: mechanistic insights and translational opportunities.","authors":"HanBin Qin, Jiaxin Sui, Shuang Wang, Xiaojing Lv, Zile Zhang, Xinhua Lin, Xuexia Liu, Hua Zhang","doi":"10.3389/falgy.2025.1631479","DOIUrl":"10.3389/falgy.2025.1631479","url":null,"abstract":"<p><p>The gut microbiota and its metabolites play important roles in the pathogenesis of various diseases. The diversity of the gut microbiota is closely related to the development and function of the human immune system. Dysbiosis, characterized by alterations in the species, quantity, and distribution of microbial community, may disrupt immune tolerance mechanisms, thereby inducing excessive immune responses to allergens and increasing the risk of allergic diseases. Various metabolites, such as short-chain fatty acids (SCFAs), bile acids, and amino acid metabolites, exert significant regulatory effects on the development of allergic diseases by modulating immune cell function, maintaining intestinal barrier integrity, and participating in signal transduction pathways. A comprehensive investigation into the relationship between allergic diseases and gut microbiota and their metabolites not only aids in elucidating the pathogenesis of allergic diseases but also provides novel insights and a theoretical foundation for developing innovative diagnostic methods, preventive strategies, and therapeutic options. This article systematically reviews the latest findings regarding the mutual influence between gut microbiota and the metabolome in host immune regulation, as well as the impact of this interaction on the development of allergic diseases, aiming to offering new strategies for the prevention and treatment of allergic diseases.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1631479"},"PeriodicalIF":3.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Multi-omics technology reveals the changes in gut microbiota to stimulate aromatic amino acid metabolism in children with allergic rhinitis and constipation.","authors":"Chunyan Wang, Haiying Liu, Xiaoli Li, Wei Kong, Hui Wu, Congfu Huang","doi":"10.3389/falgy.2025.1655751","DOIUrl":"10.3389/falgy.2025.1655751","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2025.1562832.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1655751"},"PeriodicalIF":3.1,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The chronological age at which small airway function starts to decline in a healthy Chinese population: a cross-sectional study.","authors":"Lili Hou, Yonglu Guo, Yurong Zhang, Zhenghua Zhu, Ningfang Lian, Ying Gong, Bairong Du, Yuanyuan Liu, Jichen Qu, Xian Zhu, Lei Zhu","doi":"10.3389/falgy.2025.1614899","DOIUrl":"10.3389/falgy.2025.1614899","url":null,"abstract":"<p><strong>Background: </strong>Small airway function naturally declines with aging. However, the precise age this decline begins in healthy Chinese individuals remains unclear. This study aimed to identify the chronological age at which small airway dysfunction (SAD) initiates and its predictors within a healthy Chinese population.</p><p><strong>Methods: </strong>We conducted a retrospective, cross-sectional, multicenter analysis of 462 adults undergoing routine health checkups. The participants underwent standard spirometry and completed questionnaires. The onset age of SAD was determined using the area under the receiver operating characteristic curves (AUCs). Univariate and multivariate analyses identified relationships between variables and SAD.</p><p><strong>Results: </strong>Healthy individuals aged 55 years or older demonstrated SAD. Age was an important independent predictor for SAD (odds ratio, 1.107; <i>P</i> < 0.001). The AUC of age for predicting SAD was 0.771 (95% CI: 0.730-0.808), which significantly increased to 0.790 (95% CI: 0.750-0.826; <i>P</i> = 0.0347) after adjusting for covariates (body mass index and sex).</p><p><strong>Conclusion: </strong>We identified SAD predictors in a healthy Chinese population with environmental exposure. An age of 55 years or older was the threshold for predicting SAD in these healthy participants.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1614899"},"PeriodicalIF":3.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case reports of subcutaneous pdC1INH in pregnancy and lactation: expanding treatment options for hereditary angioedema in Portugal.","authors":"Ana Luísa Pinhal, Natacha Santos, Eunice Dias de Castro","doi":"10.3389/falgy.2025.1604440","DOIUrl":"10.3389/falgy.2025.1604440","url":null,"abstract":"<p><p>Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of subcutaneous and/or submucosal angioedema. Pregnancy and breastfeeding may be associated with an increased frequency of attacks. Plasma-derived C1 inhibitor (pdC1INH) is the recommended first-line treatment for long-term prophylaxis (LTP) in these special populations. The pdC1INH currently available in Portugal is one intravenous (IV) formulation not approved for LTP, as are the other IV and subcutaneous (SC) formulations. This report documents the first cases of SC pdC1INH use during pregnancy and breastfeeding in Portugal. It describes two cases of 37-year-old women with HAE type 1 treated with SC pdC1INH as LTP during pregnancy and lactation. Both patients had been previously treated with tranexamic acid. In the first case, the patient was started on IV pdC1INH at 8 weeks' gestation due to clinical deterioration. Due to difficult IV access and inability to space out administrations, SC pdC1INH at a dose of 4,000 U (∼43.5 U/kg) every 72 h was started at 21 weeks' gestation. Administration intervals were progressively increased to 96 and later 120 h. LTP was continued throughout lactation. In the second case, LTP was not administered during pregnancy. However, after delivery, the patient experienced a worsening of angioedema episodes during breastfeeding, which persisted despite tranexamic acid treatment. SC pdC1INH was started six months postpartum at a dose of 2,000 U (∼45 U/kg) twice weekly. The administration interval was later increased to 120 h. Both patients remained free of angioedema episodes and reported no systemic adverse events. The safety of SC pdC1INH was consistent with reports in the literature. Overall, these positive results support the future use of SC pdC1INH in a broader population of pregnant and lactating women in clinical practice.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1604440"},"PeriodicalIF":3.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis.","authors":"Cheng Yang, Ling Guo, Yuhan Wang, Wenjing Jiang, Sijia Chen, Qingjia Gu","doi":"10.3389/falgy.2025.1599797","DOIUrl":"10.3389/falgy.2025.1599797","url":null,"abstract":"<p><strong>Purpose: </strong>This review aims to explore the pathophysiological mechanisms and emerging therapies for type 2 chronic rhinosinusitis with nasal polyps (CRSwNP), driven primarily by type 2 inflammation.</p><p><strong>Search methods: </strong>A comprehensive search of relevant literature was performed in databases including PubMed, Web of Science, and Scopus, using keywords such as \"chronic rhinosinusitis with nasal polyps,\" \"type 2 inflammation,\" \"Th2 cells,\" \"ILC2s,\" \"epithelial barrier dysfunction,\" and \"biologics\". The search was limited to articles published from January 2010 to February 2025.</p><p><strong>Search results: </strong>A total of 200 articles were initially retrieved. After screening based on relevance and quality, 163 articles were selected for this review. These included 109 basic research papers, 30 clinical studies, and 24 review articles.</p><p><strong>Conclusions: </strong>Type 2 CRSwNP pathogenesis involves Th2/ILC2-IL-4/IL-13 synergy, driving eosinophilic inflammation and tissue remodeling via a self-amplifying loop. Programmed cell death protein 1 and programmed death-ligand 1 dysregulation intensifies Th2 responses. Epithelial barrier defects (via disrupted junctions and ciliary defects) and epithelial-mesenchymal transition facilitate pathogen invasion and stromal changes. M2 macrophages amplify inflammation via CCL-24 and <i>Staphylococcus aureus</i> synergy, sustaining biofilm persistence. Targeted biologics-dupilumab (IL-4Rα inhibitor) reduces polyp burden and restores smell, while mepolizumab (anti-IL-5) and omalizumab (anti-IgE) address specific endotypes. Despite therapeutic advances, biologics require real-world validation for long-term safety and cost-effectiveness.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1599797"},"PeriodicalIF":3.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine signaling defects in primary atopic diseases-an updated review.","authors":"Vaishali Thakur, Rakesh Kumar Pilania, Arunima Sharma, Saniya Sharma, Alfred Thomas Mario, Taru Goyal, Madhubala Sharma, Gayathri Coimbatore Vaitheeswaran, Pandiarajan Vignesh, Surjit Singh, Manpreet Dhaliwal, Amit Rawat","doi":"10.3389/falgy.2025.1617714","DOIUrl":"10.3389/falgy.2025.1617714","url":null,"abstract":"<p><p>Primary atopic disorders (PADs) are monogenic conditions associated with severe, early-onset atopic diseases. Clinically, they often overlap with polygenic allergic conditions, making specialized laboratory testing necessary to distinguish them from polygenic atopy. Multisystem involvement, such as growth failure, recurrent infections, and autoimmunity, points towards PADs warranting further investigations. PADs associated with immune dysregulation can be broadly categorized into four mechanistic groups: those affecting the regulation of cell cytoskeleton dynamics, T-cell receptor (TCR) signaling and repertoire diversity, and function of regulatory T cell (Treg), and cytokine signaling. In this review, we have examined the defects in cytokine signaling pathways associated with PADs. Key cytokine signaling pathways implicated in PADs include the STAT3, JAK1/STAT5b, and TGF-β pathways. Pathogenic variants in these pathways result in complex clinical phenotypes but share a common theme of Th2 polarization and severe atopic manifestations. Early and accurate differentiation between polygenic atopy and PADs is crucial, as it allows for timely, targeted immunological or genetic interventions that may significantly improve patient outcomes.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1617714"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the frontline of medical care.","authors":"D M Conti, V Backer, K Aanaes, A Azizi, P W Hellings, S Lau, G Liva, G K Scadding, S Toppila-Salmi","doi":"10.3389/falgy.2025.1581694","DOIUrl":"10.3389/falgy.2025.1581694","url":null,"abstract":"<p><p>The Upper and Lower Airways Northern European Consensus (ULANC) and the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized their first workshop in Copenhagen in January 2024. The aim of the \"<i>Primary care physicians and nurses with an interest in Global Airway Diseases 2024\"</i> was to bring the concept of the global airway to the front line of medical care. ULANC is a multidisciplinary European consortium, that aims to improve the management of comorbid ear, nose and throat (ENT) conditions, such as chronic rhinosinusitis with nasal polyposis (CRSwNP), in patients also suffering from asthma. EUFOREA is an international non-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of ULANC and EUFOREA was reflected in the keynote lectures and workshop faculty coming from the allergology, pulmonology, ENT, and primary health care fields around the central theme of global airway diseases. The current report aims at providing a comprehensive overview of the key statements by the faculty of the \"Primary care physicians and nurses with interest in Global Airway Diseases 2024\", allowing all stakeholders in the respiratory field to be up-dated and ready to join forces in Europe and beyond.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1581694"},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tropomyosin-based cross-reactivity and asymptomatic shellfish sensitization in patients with perennial allergy.","authors":"Moritz Maximilian Hollstein, Marie Charlotte Schuppe, Katharina Klara Hahn, Prasad Dasari, Susann Forkel, Caroline Beutner, Timo Buhl","doi":"10.3389/falgy.2025.1598583","DOIUrl":"10.3389/falgy.2025.1598583","url":null,"abstract":"<p><strong>Background: </strong>Mite, cockroach, and shellfish (crab, clam, and shrimp) proteins share allergenic epitopes. The determination of specific IgE (sIgE) against cockroach (<i>Blattella germanica,</i> relevant in asthma) and shellfish allergens (relevant in food allergy) using whole-body extracts necessitates detailed knowledge of IgE cross-reactivity.</p><p><strong>Objective: </strong>This study aimed to evaluate whether cross-reactivity between aeroallergens and food allergens is clinically relevant and whether subjects with mite and/or cockroach sensitization are at risk of false-positive results in shellfish food allergy diagnostics.</p><p><strong>Methods: </strong>In this cross-sectional, single-center study, we recruited 200 patients with elevated sIgE against ≥1 allergen at random from our outpatient clinic and assessed allergic comorbidity. We analyzed sIgE against mites (<i>Dermatophagoides pteronyssinus, Dermatophagoides farinae,</i> or <i>Blomia tropicalis</i>), German cockroach (<i>B. germanica</i>), crab, clam, and shrimp whole allergen extract, as well as sIgE against mite tropomyosin Der p 10 and shrimp tropomyosin Pen a 1 (in a subpopulation), using automated ImmunoCAP Specific IgE Tests.</p><p><strong>Results: </strong>During allergologic assessment, two participants reported previous anaphylaxis to fish and/or seafood and were excluded from further analysis. The final study population comprised 150 female and 48 male participants. Of these, 93 presented with positive sIgE against mites. As expected, participants with mite sensitization displayed an elevated prevalence of perennial asthma or allergic rhinitis (<i>p</i> < 0.001). Further, they were more often sensitized to German cockroach, crab, claw, or shrimp (each <i>p</i> < 0.001). Der p 10 and Pen a 1 sIgE levels were below the cutoff level (<0.35 kU/L) in all subjects. However, the correlation analyses revealed that tropomyosin sIgE explained between 24% and 55% of the variance (R²) in sIgE against clam, crab, German cockroach, or shrimp (each <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Patients with mite sensitization have higher asymptomatic sIgE levels to shellfish. Even in patients with anti-tropomyosin sIgE levels below the cutoff level, anti-tropomyosin sIgE correlates strongly with sIgE against German cockroach, crab, clam, and shrimp. Our findings suggest large-scale false-positive results for sIgE to shellfish when analyzing patients with mite- or cockroach sensitization.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1598583"},"PeriodicalIF":3.3,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12245884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}